Olivier Jean Bohuon

LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark.

Essex Woodlands Management, Inc. (EW Healthcare Partners) is a private equity firm founded in 1985 by Jim L. Currie and Martin P. Sutter. The firm is headquartered in Houston, Texas.

Academie des Technologies engages in the technology industry. The company was founded in December 2000 and is headquartered in Paris, France.

Laboratoires Majorelle SAS operates as an independent French pharmaceutical company. Its products include Vitaros, Optilov, Keat range, and Carmex. The company was founded by Guillaume El Glaoui in 2012 and is headquartered in Paris, France.

Smith & Nephew A/S operates as a is a global medical technology business. It specializes in healthcare, medical supplies, medical devices, wound care, orthopaedic reconstruction and sports medicine. The company was founded by Thomas James Smith in 1856 and is headquartered in Horsholm, Denmark.

AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018.